Tang et al. demonstrated that knocking out the endogenous TGF-β receptor II (TGFBR2) in CAR-T cells with CRISPR/Cas9 technology could reduce the induced the conversion of Tregs and prevent the exhaustion of CAR-T cells, and TGFBR2-edited CAR-T cells showed better in vivo tumor elimination efficacy both in cell line-derived xenograft and patient-derived xenograft solid tumor models [70]. Here, TGFBR2 is linked to neoplasm.